Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 25:14:1468248.
doi: 10.3389/fonc.2024.1468248. eCollection 2024.

Nodal radiotherapy for prostate adenocarcinoma recurrence: predictive factors for efficacy

Anna Gueiderikh  1   2 , Jérémy Baude  3 , David Baron  2 , Renaud Schiappa  4 , Sandrine Katsahian  5   6   7   8 , Damien Moreau  1 , Marc Laurans  1 , Jean-Emmanuel Bibault  1   5 , Sarah Kreps  1 , Pierre-Yves Bondiau  2 , Magali Quivrin  3 , Alexis Lépinoy  9 , David Pasquier  10   11 , Jean-Michel Hannoun-Levi  2 , Philippe Giraud  1   5
Affiliations

Nodal radiotherapy for prostate adenocarcinoma recurrence: predictive factors for efficacy

Anna Gueiderikh et al. Front Oncol. .

Abstract

Background: Nodes are the second site for prostate cancer recurrence. Whole-pelvic radiotherapy (WPRT) has shown superiority over nodal stereotactic body radiotherapy (SBRT) in two retrospective cohorts. We aimed to compare both modalities and assess factors associated with treatment outcomes.

Materials and methods: This retrospective multicentric cohort study included patients from five institutions spanning from 2010 to 2022. Patients had a history of prostatic adenocarcinoma classified as N0 M0 at diagnosis with a first nodal-only pelvic castration-sensitive recurrence. Failure-free survival (FFS) was defined as the time from the end of RT to the first failure event-biochemical or imaging recurrence, or death.

Results: A total of 147 patients (pts) were analyzed, mainly treated for a recurrence after initial prostatectomy (87%), with 64 (43.5%) undergoing SBRT and 83 (56.5%) undergoing WPRT. SBRT was chosen mainly for dosimetric constraints (67%) and was associated with a lower rate of concomitant androgen deprivation therapy (ADT) prescription. With a median follow-up of 68 months [inter-quartile range (IQR) = 51], FFS was significantly lower in the SBRT group (p < 0.0001). In multivariable analysis, WPRT and ADT were associated with a longer FFS. Factors associated with a longer FFS after SBRT included associated ADT, lower prostate-specific antigen (PSA) levels, a PSA doubling time >6 months, and a Gleason score <8. SBRT was associated with a lower rate of genitourinary and gastrointestinal grade ≥2 complications.

Discussion: For an isolated pelvic nodal prostate cancer recurrence, SBRT is associated with a shorter FFS compared to WPRT. SBRT is often more convenient for patients and leaves further pelvic salvage options available, so it can be explored as an option for well-informed patients.

Keywords: PSA doubling time; SBRT (stereotactic body radiation therapy); androgen deprivation therapy (ADT); nodal recurrence; prostate adenocarcinoma; whole pelvic radiation therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Survival data. (A) Failure-free survival. (B) Overall survival. (C) Local control. (D) Progression-free survival. SBRT, stereotactic body radiotherapy; WPRT, whole-pelvic radiotherapy.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Amling CL, Blute ML, Bergstralh EJ, Seay TM, Slezak J, Zincke H. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol. (2000) 164:101−5. doi: 10.1016/S0022-5347(05)67457-5 - DOI - PubMed
    1. Han M, Partin AW, Pound CR, Epstein JI, Walsh PC. LONG-TERM BIOCHEMICAL DISEASE-FREE AND CANCER-SPECIFIC SURVIVAL FOLLOWING ANATOMIC RADICAL RETROPUBIC PROSTATECTOMY: the 15-year johns hopkins experience. Urol Clinics North America. (2001) 28:555−65. doi: 10.1016/S0094-0143(05)70163-4 - DOI - PubMed
    1. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. . Death in patients with recurrent prostate cancer after radical prostatectomy: prostate-specific antigen doubling time subgroups and their associated contributions to all-cause mortality. JCO. (2007) 25:1765−71. doi: 10.1200/JCO.2006.08.0572 - DOI - PubMed
    1. Evans JD, Jethwa KR, Ost P, Williams S, Kwon ED, Lowe VJ, et al. . Prostate cancer–specific PET radiotracers: A review on the clinical utility in recurrent disease. Pract Radiat Oncol. (2018) 8:28−39. doi: 10.1016/j.prro.2017.07.011 - DOI - PubMed
    1. Brand DH, Parker JI, Dearnaley DP, Eeles R, Huddart R, Khoo V, et al. . Patterns of recurrence after prostate bed radiotherapy. Radiother Oncol. (2019) 141:174−80. doi: 10.1016/j.radonc.2019.09.007 - DOI - PubMed

LinkOut - more resources